Skip to content

Author

Hao-Sheng Feng

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Targeting triple-negative breast cancer: Molecular basis and emerging antibody-drug conjugate strategies.

Triple-negative breast cancer (TNBC) accounts for ~10-15% of all breast cancers and is an aggressive, molecularly heterogeneous subtype associated with poor clinical outcomes and limited targeted treatment options. Consequently, systemic therapy has historically relied on chemotherapy, which is often compromised by rec...

Hao-Sheng Feng, Chiranjeevi Padala, Bin Liu · 0 citations
Review Open access Aug 2026

Ultrahigh-DAR antibody–drug conjugates: advancing the next generation of targeted therapy

Abstract Conventional antibody–drug conjugates (ADCs) are typically limited to drug-to-antibody ratios (DARs) of ≤8 because of restricted conjugation sites and unfavorable physicochemical properties at higher DARs, including increased hydrophobicity, aggregation, and rapid systemic clearance. Consequently, most clinica...

Hao-Sheng Feng, Bin Liu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.